JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on Replimune Group and raised the price target from $14 to $17.
September 24, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan has increased its price target for Replimune Group from $14 to $17, maintaining an Overweight rating. This suggests confidence in the company's future performance.
The increase in price target from $14 to $17 by JP Morgan, along with maintaining an Overweight rating, indicates a positive outlook on Replimune Group's future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100